Provided by Tiger Trade Technology Pte. Ltd.

VistaGen Therapeutics

0.2361
-0.0101-4.10%
Post-market: 0.2351-0.0010-0.42%19:52 EDT
Volume:403.63K
Turnover:96.30K
Market Cap:10.48M
PE:-0.14
High:0.2445
Open:0.2398
Low:0.2360
Close:0.2462
52wk High:5.14
52wk Low:0.1980
Shares:44.38M
Float Shares:41.42M
Volume Ratio:0.31
T/O Rate:0.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6559
EPS(LYR):-1.8303
ROE:-166.46%
ROA:-83.21%
PB:0.43
PE(LYR):-0.13

Loading ...

VistaGen Therapeutics Updates Executive Severance and Control Plan

TIPRANKS
·
17 hours ago

VistaGen Expands Executive Severance Plan to Cover Terminations Without Cause Outside Change-in-Control Events

Reuters
·
18 hours ago

SRX Global says adds investment in Onconetix

TIPRANKS
·
Sep 25

SRX Global Adds Minority Equity Stake in Onconetix

Reuters
·
Sep 25

Srx Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: Onco)

THOMSON REUTERS
·
Sep 25

VistaGen Reports Exploratory Trial Data Show Fasedienol Eases Anxiety in Very Severe Social Anxiety Subgroup

Reuters
·
Sep 24

Analysts Have Conflicting Sentiments on These Healthcare Companies: Codexis (CDXS) and VistaGen Therapeutics (VTGN)

TIPRANKS
·
Sep 23

Vistagen Therapeutics, - Fasedienol Nasal Spray Well-Tolerated with no New Drug-Related Safety Findings After 12 Months

THOMSON REUTERS
·
Sep 22

Vistagen Therapeutics, - no Serious Adverse Events Related to Fasedienol Reported

THOMSON REUTERS
·
Sep 22

Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of Palisade-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

THOMSON REUTERS
·
Sep 22

Vistagen Therapeutics, - Discontinuation Rate Due to Adverse Events was 1.6%, None Attributed to Fasedienol

THOMSON REUTERS
·
Sep 22

Vistagen Therapeutics, - Preparing to Meet with FDA This Quarter for Proposed New Phase 3 Trial

THOMSON REUTERS
·
Sep 22

VistaGen Therapeutics Holds Annual Shareholder Meeting

Reuters
·
Sep 11

VistaGen Reports Phase 3 Fasedienol Shows Positive Efficacy Signal in Severe Social Anxiety Subgroup Analysis

Reuters
·
Sep 10

Inflammation Drug Developer HCW Biologics' Q2 Net Loss Widens

Reuters
·
Aug 15

VistaGen Therapeutics Q1 EPS $(0.30) Beats $(0.36) Estimate, Sales $1.476M Beat $250.000K Estimate

Benzinga Earnings
·
Aug 14

VistaGen Q1 Revenue Rises on Licensing Agreement Expiration

Reuters
·
Aug 14

VistaGen Q1 EPS USD -0.3

Reuters
·
Aug 14

Vistagen Q1 Net Income USD -13.03 Million

THOMSON REUTERS
·
Aug 14

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

THOMSON REUTERS
·
Aug 14